Dose-escalation study to evaluate safety, biological and early clinical effect of CALY-002 in healthy volunteers and patients with Celiac Disease and Eosinophilic Esophagitis Kumar Jeetendra | November 16, 2020 AMSTERDAM, The Netherlands, November 16, 2020 Calypso Biotech, a company developing Interleukin-15-targeted biologics, today announced completion of dosing of first cohort of healthy subjects in the first Phase 1 clinical trial of CALY-002, a novel humanized monoclonal antibody neutralizing IL-15. “CALY-002 is the lead program of our differentiated pipeline of IL-15-targeting biologics, that we plan …
Antibiotics directed before age 2 are connected to ongoing conditions Kumar Jeetendra | November 16, 2020 In a retrospective case study, Mayo Clinic researchers have found that antibiotics administered to children younger than 2 are associated with several ongoing illnesses or ailments, which range from allergies to obesity. The findings appear in Mayo Clinic Proceedings. Using health record data from the Rochester Epidemiology Project, a population-based research cooperation in Minnesota and …
